Document is current
Any future updates will be listed below
-
Authors
Wijbenga, Nynke https://orcid.org/0000-0003-1681-3324
Muntinga, Annelot J. https://orcid.org/0009-0004-1311-4450
Goedendorp-Sluimer, Marleen M.
van Dijk, Britt C. J. https://orcid.org/0009-0007-3156-2232
Roest, Stefan https://orcid.org/0000-0003-0195-7499
Brugts, Jasper J. https://orcid.org/0000-0002-5522-9318
Caliskan, Kadir https://orcid.org/0000-0002-3293-9261
Constantinescu, Alina A.
Zandbergen, Adrienne A. M. https://orcid.org/0000-0001-5056-5921
Bos, Daniel https://orcid.org/0000-0001-8979-2603
Hellemons, Merel E. https://orcid.org/0000-0002-6666-5027
Manintveld, Olivier C. https://orcid.org/0000-0002-2202-7314
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 6 October 2025
First Online: 10 November 2025
Declarations
:
: NW: has no conflicts of interest to disclose. AM: has no conflicts of interest to disclose. MG: has no conflicts of interest to disclose. BvD: has no conflicts of interest to disclose. SR: has no conflicts of interest to disclose. JB: JB received an independent research grant from Abbott for IIS paid to the Institute and has had speaker engagements or advisory boards with Astra Zeneca, Abbott, Boehringer, Bayer, Novartis and Vifor in the past 5 years, all outside the submitted work. KC: has no conflicts of interest to disclose. AC: has no conflicts of interest to disclose. AZ: has no conflicts of interest to disclose. DB: has no conflicts of interest to disclose. OM: OM reports speaker engagement or advisory board fees from Astra Zeneca, Abbott, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, Siemens and Vifor. MH: has no conflicts of interest to disclose.
